Your browser doesn't support javascript.
loading
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.
Cabezón, Marta; Bargay, Joan; Xicoy, Blanca; García, Olga; Borrás, Josep; Tormo, Mar; Marcé, Sílvia; Pedro, Carme; Valcárcel, David; Jiménez, Maria-José; Guàrdia, Ramón; Palomo, Laura; Brunet, Salut; Vall-Llovera, Ferran; Garcia, Antoni; Feliu, Evarist; Zamora, Lurdes.
Afiliação
  • Cabezón M; Hematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Bargay J; Departament de Medicina, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Xicoy B; Hematology Service, Hospital Son Llàtzer, Mallorca, Spain.
  • García O; Hematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Borrás J; Josep Carreras Leukemia Research Institute, Campus Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Tormo M; Hematology Service, Hospital Son Llàtzer, Mallorca, Spain.
  • Marcé S; Hematology Service, Hospital Clínic de Valencia, Valencia, Spain.
  • Pedro C; Hematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Valcárcel D; Hematology Service, Hospital del Mar, Barcelona, Spain.
  • Jiménez MJ; Hematology Service, Hospital Vall d'Hebron, Barcelona, Spain.
  • Guàrdia R; Hematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Palomo L; Hematology Service, ICO Girona-Hospital Josep Trueta, Girona, Spain.
  • Brunet S; Josep Carreras Leukemia Research Institute, Campus Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Vall-Llovera F; Hematology Service, Hospital de Sant Pau, Barcelona, Spain.
  • Garcia A; Hematology Service, Hospital Mútua de Terrassa, Terrassa, Spain.
  • Feliu E; Hematology Service, Hospital Arnau de Vilanova, Lleida, Spain.
  • Zamora L; Hematology Service, ICO Badalona-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
Oncotarget ; 9(27): 19342-19355, 2018 Apr 10.
Article em En | MEDLINE | ID: mdl-29721207
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. Overall, 95% of patients harbored at least one mutation. TP53, DNMT3A and SRSF2 were the most frequently altered genes. Mutations in TP53 correlated with higher risk features and shorter overall survival (OS) and progression free survival (PFS) in univariate analysis. Patients with SRSF2 mutations were associated with better OS and PFS. Response rate was 55%; but we could not correlate the presence of TET2 and TP53 mutations with AZA response. Patients with sAML presented more variations than patients with high-risk MDS, and usually at relapse the number of mutations increased, supporting the idea that in advanced stages of the disease there is a greater genomic complexity. These results confirm that mutation analysis can add prognostic value to high-risk MDS and sAML patients, not only at diagnosis but also at follow-up.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha País de publicação: Estados Unidos